Tamsulosin Hydrochloride
Product Images NDC 67296-1850

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 67296-1850). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-1 (Tamsulosin Fig1)

A pharmacokinetic plasma concentration versus time graph comparing Tamsulosin Hydrochloride levels under fasted and fed conditions. Plasma concentration (ng/mL) is plotted on the vertical axis and time (hours) on the horizontal axis. The graph displays two curves showing drug concentration changes over 36 hours.*

FDA Label Image

Figure-2a (Tamsulosin Fig2a)

A line graph showing the mean change over duration of treatment in weeks for Tamsulosin Hydrochloride at doses of 0.4 mg and 0.8 mg compared to placebo. The graph illustrates a greater mean change decrease with both Tamsulosin doses relative to placebo over a 13-week period, with sample sizes noted below the x-axis.*

FDA Label Image

Figure-2b (Tamsulosin Fig2b)

A line graph showing the mean change over duration of treatment in weeks for Tamsulosin Hydrochloride at doses of 0.8 mg and 0.4 mg compared to placebo. The x-axis represents weeks of treatment from 0 to 13 plus last observation carried forward (LOCF), while the y-axis represents the mean change. Three lines plot the response for 0.8 mg dose (circles), 0.4 mg dose (triangles), and placebo (squares), with both doses showing greater mean reductions than placebo.*

FDA Label Image

Tamsulosin-fig3a (Tamsulosin Fig3a)

A line graph displaying mean change in milliliters per second (mL/sec) over duration of treatment in weeks for Tamsulosin Hydrochloride at 0.8 mg and 0.4 mg doses compared with placebo. The graph shows three treatment groups plotted over a 13-week period plus last observation carried forward (LOCF), with sample sizes indicated below each time point.*

FDA Label Image

Tamsulosin-fig3b (Tamsulosin Fig3b)

A line graph showing mean change in mL/sec over duration of treatment in weeks for Tamsulosin Hydrochloride at dosages 0.8 mg, 0.4 mg, and placebo. The x-axis represents treatment duration from 0 to 13 weeks plus LOCF, and the y-axis shows mean change ranging from 0 to 3 mL/sec. Three lines compare changes: 0.8 mg (circles), 0.4 mg (triangles), and placebo (squares). Sample sizes at each time point are noted below the x-axis.*

FDA Label Image

Tamsulosin-label (Tamsulosin Label)

Label for Tamsulosin Hydrochloride Capsules, USP 0.4 mg by Sun Pharmaceutical Industries, distributed by Sun Pharmaceutical Industries, Inc. The capsule count is 90. Storage instructions and dosing advisories are included, along with contact information and a barcode.*

FDA Label Image

Chemical-structure (Tamsulosin Str)

Chemical structure diagram of Tamsulosin Hydrochloride showing its molecular arrangement with aromatic rings, functional groups, and hydrochloride component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.